Sexually Transmitted Diseases Testing Market by Disease Type and Location of Testing : Global Opportunity Analysis and Industry Forecast, 2021-2030

Sexually Transmitted Diseases (STD) Testing Market by Disease Type (Chlamydia, Gonorrhea, Herpes Simplex Virus, Syphilis, Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), and Other Diseases) and Location of Testing (Laboratory Testing, and Point-of-care (POC) Testing): Global Opportunity Analysis and Industry Forecast, 2021-2030

The STD testing market accounted for $91,445.93 million in 2020, and is expected to reach $1,50,445.01 million by 2030, registering a CAGR of 5.1% from 2021 to 2030. Sexually transmitted diseases (STDs) are considered as one of the most critical health challenges globally. Chlamydia, gonorrhea, and herpes simplex virus are some of the highly prevalent STDs. The STD testing market has witnessed significant growth in the past decade with increasing prevalence of STDs. With high prevalence, coverage of STD diagnosis facilities has also majorly increased in the developed countries. However, in developing regions, STD diagnosis facilities are still inadequate to provide wider coverage to the population with STDs. Inadequate facilities for STD diagnosis are the major concern in developing regions.
STDs have witnessed substantial growth in their prevalence and incidents in the past decade. With increasing prevalence, respective countries across the world are focusing on implementation of national screening programs to expand the coverage of STD diagnosis. Moreover, reimbursement policies have also been favorable for STD services. These factors are significantly driving the growth of the global STD testing market. On the other hand, limited access to STD diagnosis in developing regions is expected to restrain the market growth.
The STD testing market is segmented on the basis of disease type, location of testing, and region. By disease type, it is divided into chlamydia, syphilis, gonorrhea, herpes simplex virus, human papillomavirus (HPV), human immunodeficiency virus testing, and others. By location of testing, the market is bifurcated into laboratory testing, and point of care (PoC) testing. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global STD Testing market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the products and end users of STD Testing used across the globe.
- Key market players and their strategies have been analysed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Disease Type
• Chlamydia
• Gonorrhea
• Herpes simplex virus
• Syphilis
• Human papillomavirus (HPV)
• Other diseases (human immunodeficiency virus (HIV), chancroid, trichomoniasis, and hepatitis B)

By Location of Testing
• Laboratory testing
• Point of care (POC) testing

• By Region
o North America
- U.S.
- Canada
- Mexico
o Europe
- Germany
- Italy
- France
- UK
- Rest of Europe
o Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
o LAMEA
- Latin America
- Middle East and Africa

KEY MARKET PLAYERS
• Abbott laboratories
• Becton Dickinson Company
• BioMérieux, Inc.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Diasorin Molecular LLC
• Hologic, Inc.
• Orasure Technologies, Inc.
• Roche Holding AG
• Thermo Fisher Scientific Inc.